ESR1 and breast cancer: Importantly, in the xenograft model, both CGA and exosome inhibitor GW4869 effectively suppressed ER+ breast cancer bone metastasis (Fig. 7a), while no notable side effects were observed with the mice received CGA treatment (Supplementary Fig. 8d, e).